BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6:519-527. [PMID: 19636327 DOI: 10.1038/nrclinonc.2009.111] [Cited by in Crossref: 292] [Cited by in F6Publishing: 271] [Article Influence: 22.5] [Reference Citation Analysis]
Number Citing Articles
1 Aust D. WHO-Klassifikation 2010 für den unteren Gastrointestinaltrakt: Was ist neu? Pathologe 2011;32:326-31. [DOI: 10.1007/s00292-011-1505-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? Oncotarget. 2017;8:100863-100898. [PMID: 29246028 DOI: 10.18632/oncotarget.19809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer 2012;48:1466-75. [DOI: 10.1016/j.ejca.2012.02.057] [Cited by in Crossref: 360] [Cited by in F6Publishing: 325] [Article Influence: 36.0] [Reference Citation Analysis]
4 Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol. 2010;21:1579-1584. [PMID: 20219759 DOI: 10.1093/annonc/mdq043] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
5 Rui YY, Zhang D, Zhou ZG, Wang C, Yang L, Yu YY, Chen HN. Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS One. 2013;8:e77901. [PMID: 24205021 DOI: 10.1371/journal.pone.0077901] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
6 Takamoto T, Hashimoto T, Miyata A, Shimada K, Maruyama Y, Makuuchi M. Repeat Hepatectomy After Major Hepatectomy for Colorectal Liver Metastases. J Gastrointest Surg 2020;24:380-7. [PMID: 30830515 DOI: 10.1007/s11605-019-04154-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mei Z, Shao YW, Lin P, Cai X, Wang B, Ding Y, Ma X, Wu X, Xia Y, Zhu D, Shu Y, Fu Z, Gu Y. SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients. BMC Cancer. 2018;18:479. [PMID: 29703253 DOI: 10.1186/s12885-018-4298-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
8 Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev 2011;244:218-31. [PMID: 22017441 DOI: 10.1111/j.1600-065X.2011.01069.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 68] [Article Influence: 10.5] [Reference Citation Analysis]
9 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
10 Ho TH, Dang KX, Lintula S, Hotakainen K, Feng L, Olkkonen VM, Verschuren EW, Tenkanen T, Haglund C, Kolho KL, Stenman UH, Stenman J. Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity. Nucleic Acids Res 2015;43:e4. [PMID: 25378315 DOI: 10.1093/nar/gku1048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
11 Polivka J, Windrichova J, Pesta M, Houfkova K, Rezackova H, Macanova T, Vycital O, Kucera R, Slouka D, Topolcan O. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases. Cancers (Basel) 2020;12:E2434. [PMID: 32867151 DOI: 10.3390/cancers12092434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Teixeira E, Silva C, Martel F. The role of the glutamine transporter ASCT2 in antineoplastic therapy. Cancer Chemother Pharmacol 2021;87:447-64. [PMID: 33464409 DOI: 10.1007/s00280-020-04218-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PLoS One. 2012;7:e41347. [PMID: 22911782 DOI: 10.1371/journal.pone.0041347] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
14 Bai H, Wang J, Phan CU, Chen Q, Hu X, Shao G, Zhou J, Lai L, Tang G. Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment. Nat Commun 2021;12:759. [PMID: 33536421 DOI: 10.1038/s41467-021-21071-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
15 Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, Ferraro S, Zani M, Nicolussi A, D'inzeo S, Coppa A, Screpanti I, Gulino A, Giannini G. Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. Clinical Biochemistry 2015;48:908-10. [DOI: 10.1016/j.clinbiochem.2015.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
16 Macedo FIB, Makarawo T. Colorectal hepatic metastasis: Evolving therapies. World J Hepatol 2014; 6(7): 453-463 [PMID: 25067997 DOI: 10.4254/wjh.v6.i7.453] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
17 Küntzer J, Eggle D, Klostermann S, Burtscher H. Human variation databases. Database (Oxford) 2010;2010:baq015. [PMID: 20639550 DOI: 10.1093/database/baq015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
18 Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30:3570-3577. [PMID: 22734028 DOI: 10.1200/jco.2012.42.2592] [Cited by in Crossref: 234] [Cited by in F6Publishing: 132] [Article Influence: 23.4] [Reference Citation Analysis]
19 Yang YSH, Ko PJ, Pan YS, Lin HY, Whang-Peng J, Davis PJ, Wang K. Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers. J Biomed Sci 2021;28:24. [PMID: 33827580 DOI: 10.1186/s12929-021-00719-5] [Reference Citation Analysis]
20 Okada S, Hata K, Kawai K, Yamamoto Y, Tanaka T, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K, Nozawa H. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports. Medicine (Baltimore) 2019;98:e14781. [PMID: 30896620 DOI: 10.1097/MD.0000000000014781] [Reference Citation Analysis]
21 He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther 2020;13:12601-13. [PMID: 33335401 DOI: 10.2147/OTT.S279312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kou T, Kanai M, Matsumoto S, Okuno Y, Muto M. The possibility of clinical sequencing in the management of cancer. Jpn J Clin Oncol 2016;46:399-406. [PMID: 26917600 DOI: 10.1093/jjco/hyw018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
23 Pachmayr E, Treese C, Stein U. Underlying Mechanisms for Distant Metastasis - Molecular Biology. Visc Med 2017;33:11-20. [PMID: 28785563 DOI: 10.1159/000454696] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
24 Zota VE, Magliocco AM. Molecular Technologies in the Clinical Diagnostic Laboratory. Cancer Control 2015;22:142-51. [PMID: 26068758 DOI: 10.1177/107327481502200204] [Reference Citation Analysis]
25 Bozzao C, Varvara D, Piglionica M, Bagnulo R, Forte G, Patruno M, Russo S, Piscitelli D, Stella A, Resta N. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. Int J Biol Markers 2012;27:366-74. [DOI: 10.5301/jbm.2012.9765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
26 Seekhuntod S, Thavarungkul P, Chaichanawongsaroj N. Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients. PLoS One 2016;11:e0147672. [PMID: 26812617 DOI: 10.1371/journal.pone.0147672] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
27 Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 2015;15:340. [PMID: 25929517 DOI: 10.1186/s12885-015-1345-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
28 Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012;13:12153-68. [PMID: 23202889 DOI: 10.3390/ijms131012153] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 10.7] [Reference Citation Analysis]
29 Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Crit Rev Oncol Hematol 2015;93:190-202. [PMID: 25459669 DOI: 10.1016/j.critrevonc.2014.10.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
30 Hsu JY, Chang KY, Chen SH, Lee CT, Chang ST, Cheng HC, Chang WC, Chen BK. Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation. Oncotarget 2015;6:1723-39. [PMID: 25595899 DOI: 10.18632/oncotarget.2783] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
31 Louey A, Hernández D, Pébay A, Daniszewski M. Automation of Organoid Cultures: Current Protocols and Applications. SLAS Discov 2021;:24725552211024547. [PMID: 34167363 DOI: 10.1177/24725552211024547] [Reference Citation Analysis]
32 Internò V, Tucci M, Pezzicoli G, Silvestris F, Porta C, Mannavola F. Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Front Oncol 2020;10:581130. [PMID: 33102237 DOI: 10.3389/fonc.2020.581130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369-383. [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014;6:1571-84. [PMID: 25484061 DOI: 10.4161/19420862.2014.975660] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
35 Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM. AXL is an oncotarget in human colorectal cancer. Oncotarget. 2015;6:23281-23296. [PMID: 25966280 DOI: 10.18632/oncotarget.3962] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
36 Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85. [PMID: 24455615 DOI: 10.4103/2278-330X.114152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
37 De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762. [PMID: 20619739 DOI: 10.1016/s1470-2045(10)70130-3] [Cited by in Crossref: 1391] [Cited by in F6Publishing: 788] [Article Influence: 115.9] [Reference Citation Analysis]
38 Sakai E, Ohata K, Chiba H, Matsuhashi N, Doi N, Fukushima J, Endo H, Takahashi H, Tsuji S, Yagi K, Matsusaka K, Aburatani H, Nakajima A, Kaneda A. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. Int J Cancer 2014;135:1586-95. [PMID: 24590867 DOI: 10.1002/ijc.28814] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
39 Satow R, Hirano T, Batori R, Nakamura T, Murayama Y, Fukami K. Phospholipase Cδ1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells. Proc Natl Acad Sci U S A 2014;111:13505-10. [PMID: 25197077 DOI: 10.1073/pnas.1405374111] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
40 López F, Llorente JL, Oviedo CM, Vivanco B, Álvarez Marcos C, García-inclán C, Scola B, Hermsen MA. Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma. Cancer 2012;118:1818-26. [DOI: 10.1002/cncr.26451] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
41 Li W, Liu Z, Li C, Li N, Fang L, Chang J, Tan J. Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression. J Cancer Res Clin Oncol 2016;142:619-32. [DOI: 10.1007/s00432-015-2067-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
42 Shen T, Guo Q. EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2. Cell Biol Int 2019. [PMID: 31368612 DOI: 10.1002/cbin.11209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
43 Day E, Dear PH, Mccaughan F. Digital PCR strategies in the development and analysis of molecular biomarkers for personalized medicine. Methods 2013;59:101-7. [DOI: 10.1016/j.ymeth.2012.08.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 116] [Article Influence: 14.2] [Reference Citation Analysis]
44 Slomovitz BM, Chelariu-Raicu A, Schmeler KM, Lu KH, Gershenson DM, Wolf J, Coleman RL. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer 2020;30:1733-7. [PMID: 33020204 DOI: 10.1136/ijgc-2020-001859] [Reference Citation Analysis]
45 Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: Roles in precision medicine. Semin Cancer Biol. 2019;59:23-35. [PMID: 31255772 DOI: 10.1016/j.semcancer.2019.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
46 Osumi H, Shinozaki E, Takeda Y, Wakatsuki T, Ichimura T, Saiura A, Yamaguchi K, Takahashi S, Noda T, Zembutsu H. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Med. 2019;8:408-417. [PMID: 30575318 DOI: 10.1002/cam4.1913] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
47 Sotelo Lezama MJ, Sastre Valera J, Díaz-Rubio García E. Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2014;14:387-99. [PMID: 24479733 DOI: 10.1517/14712598.2014.883376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ioannou P, Talesnik J. Platelet antiaggregatory substances inhibit arachidonic acid induced coronary constriction. Can J Physiol Pharmacol 1986;64:398-405. [PMID: 2425912 DOI: 10.1139/y86-064] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 1.4] [Reference Citation Analysis]
49 Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012;13:1-13. [PMID: 22198566 DOI: 10.4161/cbt.13.1.18438] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
50 Morgillo F, Martinelli E, Troiani T, Orditura M, De Vita F, Ciardiello F. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS One 2011;6:e28841. [PMID: 22174910 DOI: 10.1371/journal.pone.0028841] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
51 Hayes DN, Kim WY. The next steps in next-gen sequencing of cancer genomes. J Clin Invest 2015;125:462-8. [PMID: 25642706 DOI: 10.1172/JCI68339] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
52 De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17-S27. [PMID: 22443084 DOI: 10.1517/14728222.2011.639361] [Cited by in Crossref: 403] [Cited by in F6Publishing: 394] [Article Influence: 40.3] [Reference Citation Analysis]
53 Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer. 2010;9:315-318. [PMID: 21208847 DOI: 10.3816/ccc.2010.n.046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
54 Hedtke M, Pessoa Rejas R, Froelich MF, Ast V, Duda A, Mirbach L, Costina V, Martens UM, Hofheinz RD, Neumaier M, Haselmann V. Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. Mol Oncol 2021. [PMID: 34873826 DOI: 10.1002/1878-0261.13156] [Reference Citation Analysis]
55 Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. Cancer Med 2017;6:928-36. [PMID: 28378527 DOI: 10.1002/cam4.1051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
56 Hsieh MC, Wu CF, Chen CW, Shi CS, Huang WS, Kuan FC. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis. Sci Rep 2018;8:2047. [PMID: 29391418 DOI: 10.1038/s41598-018-19835-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
57 Signore M, Buccarelli M, Pilozzi E, De Luca G, Cappellari M, Fanciulli M, Goeman F, Melucci E, Biffoni M, Ricci-Vitiani L. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget 2016;7:44113-28. [PMID: 27286453 DOI: 10.18632/oncotarget.9859] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
58 Park JJ, Lee M. Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. Gut Liver 2013;7:629-41. [PMID: 24312702 DOI: 10.5009/gnl.2013.7.6.629] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
59 Kamel HFM, Al-Amodi HSAB. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics Proteomics Bioinformatics 2017;15:220-35. [PMID: 28813639 DOI: 10.1016/j.gpb.2016.11.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
60 Wong H, Yau T. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol. 2013;6:15-31. [PMID: 23320047 DOI: 10.1177/1756283x12453636] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
61 de Melo-Silva AJ, Lucena JP, Hueneburg T. The evolution of molecular diagnosis using digital polymerase chain reaction to detect cancer via cell-free DNA and circulating tumor cells. Cell Biol Int 2020;44:735-43. [PMID: 31829466 DOI: 10.1002/cbin.11286] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Giusti K, Young AQ, Lehrhaupt K. Closing Knowledge Gaps to Optimize Patient Outcomes and Advance Precision Medicine. Cancer J 2018;24:144-51. [PMID: 29794540 DOI: 10.1097/PPO.0000000000000319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Pillai RK, Lopategui JR, Dhall D, Guindi M, Slavin T, Lofton-Day CE, Patterson SD. The State of the Art in Colorectal Cancer Molecular Biomarker Testing. Adv Anat Pathol 2016;23:92-103. [PMID: 26849815 DOI: 10.1097/PAP.0000000000000107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates. Exp Mol Pathol 2017;102:475-83. [PMID: 28506769 DOI: 10.1016/j.yexmp.2017.05.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
65 Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G, Ciardiello F, Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013;14:1143-6. [PMID: 24025416 DOI: 10.4161/cbt.26340] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
66 Wang G, Kelley RK, Gappnet. KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. PLoS Curr 2010;2:RRN1175. [PMID: 20877448 DOI: 10.1371/currents.RRN1175] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
67 Yoon S, Eom GH. Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation. Chonnam Med J 2020;56:6-11. [PMID: 32021836 DOI: 10.4068/cmj.2020.56.1.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 García-Inclán C, López F, Pérez-Escuredo J, Cuesta-Albalad MP, Vivanco B, Centeno I, Balbín M, Suárez C, Llorente JL, Hermsen MA. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas. Cell Oncol (Dordr) 2012;35:443-50. [PMID: 23055340 DOI: 10.1007/s13402-012-0103-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
69 Pérez-Báez W, García-Latorre EA, Maldonado-Martínez HA, Coronado-Martínez I, Flores-García L, Taja-Chayeb L. Impact of fixation artifacts and threshold selection on high resolution melting analysis for KRAS mutation screening. Mol Cell Probes 2017;35:34-43. [PMID: 28627450 DOI: 10.1016/j.mcp.2017.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
70 Yang J, Yang T, Yan W, Li D, Wang F, Wang Z, Guo Y, Bai P, Tan N, Chen L. TAK1 inhibition by natural cyclopeptide RA-V promotes apoptosis and inhibits protective autophagy in Kras-dependent non-small-cell lung carcinoma cells. RSC Adv 2018;8:23451-8. [DOI: 10.1039/c8ra04241a] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
72 Lee YS, Chin YT, Yang YSH, Wei PL, Wu HC, Shih A, Lu YT, Pedersen JZ, Incerpi S, Liu LF, Lin HY, Davis PJ. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status. Steroids 2016;111:63-70. [PMID: 26980146 DOI: 10.1016/j.steroids.2016.03.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
73 Salem ME, Puccini A, Tie J. Redefining Colorectal Cancer by Tumor Biology. Am Soc Clin Oncol Educ Book 2020;40:1-13. [PMID: 32207671 DOI: 10.1200/EDBK_279867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16:1557-1564. [PMID: 22016477 DOI: 10.1634/theoncologist.2011-0141] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
75 Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J 2010;16:262-72. [PMID: 20526105 DOI: 10.1097/PPO.0b013e3181e07738] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
76 Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio A, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Annals of Oncology 2014;25:1756-61. [DOI: 10.1093/annonc/mdu230] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 10.8] [Reference Citation Analysis]
77 Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A 2012;109:E353-9. [PMID: 22203991 DOI: 10.1073/pnas.1105026109] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
78 Serrano C, Markman B, Tabernero J. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. Cancer J 2010;16:226-34. [PMID: 20526101 DOI: 10.1097/PPO.0b013e3181e07670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
79 Li Y, Monzo M, Moreno I, Martinez-Rodenas F, Hernandez R, Castellano JJ, Canals J, Han B, Muñoz C, Navarro A. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients. Int J Colorectal Dis 2020;35:805-13. [PMID: 32088737 DOI: 10.1007/s00384-020-03538-6] [Reference Citation Analysis]
80 Kraus S, Nabiochtchikov I, Shapira S, Arber N. Recent advances in personalized colorectal cancer research. Cancer Lett 2014;347:15-21. [PMID: 24491406 DOI: 10.1016/j.canlet.2014.01.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
81 Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. J Transl Med 2015;13:287. [PMID: 26335936 DOI: 10.1186/s12967-015-0655-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
82 Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10:671-684. [PMID: 21878982 DOI: 10.1038/nrd3504] [Cited by in Crossref: 939] [Cited by in F6Publishing: 865] [Article Influence: 85.4] [Reference Citation Analysis]
83 Puppa G. TNM staging system of colorectal carcinoma: surgical pathology of the seventh edition. Diagnostic Histopathology 2011;17:243-62. [DOI: 10.1016/j.mpdhp.2011.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
84 Viray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL. Automated objective determination of percentage of malignant nuclei for mutation testing. Appl Immunohistochem Mol Morphol 2014;22:363-71. [PMID: 24162261 DOI: 10.1097/PAI.0b013e318299a1f6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
85 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369-383. [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
86 Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small GTPases 2012;3:34-9. [PMID: 22714415 DOI: 10.4161/sgtp.18751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
87 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Res 2014;74:5152-64. [PMID: 25136066 DOI: 10.1158/0008-5472.CAN-14-0294] [Cited by in Crossref: 120] [Cited by in F6Publishing: 82] [Article Influence: 15.0] [Reference Citation Analysis]
88 Cho YH, Cha PH, Kaduwal S, Park JC, Lee SK, Yoon JS, Shin W, Kim H, Ro EJ, Koo KH, Park KS, Han G, Choi KY. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer. Oncotarget 2016;7:81727-40. [PMID: 27835580 DOI: 10.18632/oncotarget.13172] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
89 El Otmani I, El Agy F, El Baradai S, Bouguenouch L, Lahmidani N, El Abkari M, Benajah DA, Toughrai I, El Bouhaddouti H, Mouaqit O, Ibn Majdoub Hassani K, Mazaz K, Benjelloun EB, Ousadden A, El Rhazi K, Bouhafa T, Benbrahim Z, Ouldim K, Ibrahimi SA, Ait Taleb K, Chbani L. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population. Dis Markers 2020;2020:8459303. [PMID: 31998419 DOI: 10.1155/2020/8459303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat 2011;130:465-75. [DOI: 10.1007/s10549-011-1360-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
91 Lee JL, Roh SA, Kim CW, Kwon YH, Ha YJ, Kim SK, Kim SY, Cho DH, Kim YS, Kim JC. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer. World J Gastroenterol 2019; 25(11): 1341-1354 [PMID: 30918427 DOI: 10.3748/wjg.v25.i11.1341] [Reference Citation Analysis]
92 Yin N, Lepp A, Ji Y, Mortensen M, Hou S, Qi XM, Myers CR, Chen G. The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem 2017;292:15070-9. [PMID: 28739874 DOI: 10.1074/jbc.M117.779488] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
93 Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M, Garcia-Toro E, Herreros-Villanueva M. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013;8:e55793. [PMID: 23437064 DOI: 10.1371/journal.pone.0055793] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
94 Möller Y, Morkel M, Schmid J, Beyes S, Hendrick J, Strotbek M, Riemer P, Schmid S, Schmitt LC, Kontermann R, Mürdter T, Schwab M, Sers C, Olayioye MA. Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget 2016;7:53526-39. [PMID: 27447549 DOI: 10.18632/oncotarget.10658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Padhan N, Nordling TE, Sundström M, Åkerud P, Birgisson H, Nygren P, Nelander S, Claesson-Welsh L. High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. BMC Cancer 2016;16:683. [PMID: 27562229 DOI: 10.1186/s12885-016-2725-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
96 Feigelson HS, Zeng C, Pawloski PA, Onitilo AA, Richards CS, Johnson MA, Kauffman TL, Webster J, Nyirenda C, Alexander GL, Hwang C, Cross D, McCarty CA, Davis RL, Schwarzkopf D, Williams AE, Honda S, Daida Y, Kushi LH, Delate T, Goddard KA; CERGEN Study Team. Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS One 2014;9:e94977. [PMID: 24788807 DOI: 10.1371/journal.pone.0094977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
97 Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol 2015;17:804-15. [PMID: 26005835 DOI: 10.1038/ncb3175] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
98 Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, Gazzaniga P. Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol Ther 2014;15:496-503. [PMID: 24521660 DOI: 10.4161/cbt.28020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
99 Li YJ, Lai WT, Chang CC, Kuo MY, Deng YT, Yang CN, Cheng SJ, Wu TS, Chen ST, Lin BR. Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression. Oral Oncol 2017;66:100-7. [PMID: 28012797 DOI: 10.1016/j.oraloncology.2016.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
100 Mack E, Stabla K, Riera-Knorrenschild J, Moll R, Neubauer A, Brendel C. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. BMC Cancer 2016;16:585. [PMID: 27485514 DOI: 10.1186/s12885-016-2589-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
101 Revuelta I, Moya-Rull D, García-Herrera A, Rovira J, Ayala de la Peña F, Misiego A, Guzmán F, Oppenheimer F, Albanell J, Campistol JM. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients. Transplantation. 2012;93:509-517. [PMID: 22245873 DOI: 10.1097/TP.0b013e318242be46] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
102 Pan Z, Liu C, Zhi Y, Xie Z, Wu L, Jiang M, Zhang Y, Zhou R, Zhao L. LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. Oncogene 2021;40:2581-95. [PMID: 33686242 DOI: 10.1038/s41388-021-01736-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Teerapakpinyo C, Wanthong P, Aumchaaumchaya M, Chankate P, Kaikeaw W, Tosakorn W, Shaungshoti S. Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer. Asian Biomedicine 2017;9:61-7. [DOI: 10.5372/1905-7415.0901.369] [Reference Citation Analysis]
104 Zuo Q, Shi M, Li L, Chen J, Luo R. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomed Pharmacother. 2010;64:550-558. [PMID: 20630698 DOI: 10.1016/j.biopha.2010.03.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
105 Wolfson E, Schmukler E, Schokoroy ST, Kloog Y, Pinkas-Kramarski R. Enhancing FTS (Salirasib) efficiency via combinatorial treatment. Biol Cell 2015;107:130-43. [PMID: 25735913 DOI: 10.1111/boc.201400087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
106 Nagahashi M, Wakai T, Shimada Y, Ichikawa H, Kameyama H, Kobayashi T, Sakata J, Yagi R, Sato N, Kitagawa Y, Uetake H, Yoshida K, Oki E, Kudo SE, Izutsu H, Kodama K, Nakada M, Tse J, Russell M, Heyer J, Powers W, Sun R, Ring JE, Takabe K, Protopopov A, Ling Y, Okuda S, Lyle S. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. Genome Med. 2016;8:136. [PMID: 28007036 DOI: 10.1186/s13073-016-0387-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
107 Tierling S, Sers C, Lehmann A, Walter J. A fast, cost-efficient and sensitive approach for KRAS mutation detection using multiplexed primer extension with IP/RP-HPLC separation. Int J Cancer 2012;130:567-74. [PMID: 21387306 DOI: 10.1002/ijc.26040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
108 Pandey K, Umar S. Microbiome in drug resistance to colon cancer. Curr Opin Physiol 2021;23:100472. [PMID: 34514218 DOI: 10.1016/j.cophys.2021.100472] [Reference Citation Analysis]
109 Fruscella M, Ponzetto A, Crema A, Carloni G. The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology. Journal of Nanotechnology 2016;2016:1-18. [DOI: 10.1155/2016/3020361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Chretien AS, Harlé A, Meyer-Lefebvre M, Rouyer M, Husson M, Ramacci C, Harter V, Genin P, Leroux A, Merlin JL. Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. Cancer Med 2013;2:11-20. [PMID: 24133623 DOI: 10.1002/cam4.47] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
111 Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 2013;8:e81628. [PMID: 24339949 DOI: 10.1371/journal.pone.0081628] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
112 Ghanta KS, Li DQ, Eswaran J, Kumar R. Gene profiling of MTA1 identifies novel gene targets and functions. PLoS One 2011;6:e17135. [PMID: 21364872 DOI: 10.1371/journal.pone.0017135] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
113 Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin 2022. [PMID: 35472088 DOI: 10.3322/caac.21728] [Reference Citation Analysis]
114 Zhao Y, Pang D, Wang C, Zhong S, Wang S. MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway. Tumour Biol 2016;37:11485-93. [PMID: 27012554 DOI: 10.1007/s13277-016-5027-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
115 Sakuma K, Aoki M, Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 2012;109:7776-81. [PMID: 22547830 DOI: 10.1073/pnas.1111135109] [Cited by in Crossref: 108] [Cited by in F6Publishing: 97] [Article Influence: 10.8] [Reference Citation Analysis]
116 Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ 2014;21:720-34. [PMID: 24440911 DOI: 10.1038/cdd.2013.196] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
117 Cai WQ, Zeng LS, Wang LF, Wang YY, Cheng JT, Zhang Y, Han ZW, Zhou Y, Huang SL, Wang XW, Peng XC, Xiang Y, Ma Z, Cui SZ, Xin HW. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Front Oncol 2020;10:1249. [PMID: 32793499 DOI: 10.3389/fonc.2020.01249] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
118 Bakkers C, Simkens GAAM, De Hingh IHJT. Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research. J Gastrointest Oncol 2021;12:S206-13. [PMID: 33968438 DOI: 10.21037/jgo-20-133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Gutting T, Weber CA, Weidner P, Herweck F, Henn S, Friedrich T, Yin S, Kzhyshkowska J, Gaiser T, Janssen KP, Reindl W, Ebert MPA, Burgermeister E. PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice. Oncoimmunology 2018;7:e1423168. [PMID: 29721374 DOI: 10.1080/2162402X.2017.1423168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
120 Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, Jackson C, Chatterjee D, Pricolo V, Roth L, Shah N, Cataldo T, Safran H, Hixson D, Quesenberry P. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol 2013;95:74-82. [PMID: 23528430 DOI: 10.1016/j.yexmp.2013.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
121 Orue A, Rieber M. Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR. PLoS One 2016;11:e0163070. [PMID: 27632281 DOI: 10.1371/journal.pone.0163070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lee MS, Kopetz S. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2015;14:203-18. [DOI: 10.1016/j.clcc.2015.05.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
123 Xu P, Wu Q, Yu J, Rao Y, Kou Z, Fang G, Shi X, Liu W, Han H. A Systematic Way to Infer the Regulation Relations of miRNAs on Target Genes and Critical miRNAs in Cancers. Front Genet 2020;11:278. [PMID: 32296462 DOI: 10.3389/fgene.2020.00278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
124 He J, Ahuja N. Personalized Approaches to Gastrointestinal Cancers: Importance of Integrating Genomic Information to Guide Therapy. Surg Clin North Am 2015;95:1081-94. [PMID: 26315525 DOI: 10.1016/j.suc.2015.05.002] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 Huang T, Zhuge J, Zhang WW. Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomark Res 2013;1:3. [PMID: 24252159 DOI: 10.1186/2050-7771-1-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
126 Auman J, Mcleod H. Now's the time to find biomarkers on purpose. Annals of Oncology 2010;21:193-4. [DOI: 10.1093/annonc/mdp571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Yin J, Jung J, Choi SI, Kim SS, Oh YT, Kim T, Choi E, Lee SJ, Kim H, Kim EO, Lee YS, Chang HJ, Park JY, Kim Y, Yun T, Heo K, Kim Y, Kim H, Kim Y, Park JB, Choi SW. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas. Cancer Letters 2018;414:181-9. [DOI: 10.1016/j.canlet.2017.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
128 Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N. Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers (Basel) 2019;11:E859. [PMID: 31226844 DOI: 10.3390/cancers11060859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
129 Turin I, Delfanti S, Ferulli F, Brugnatelli S, Tanzi M, Maestri M, Cobianchi L, Lisini D, Luinetti O, Paulli M, Perotti C, Todisco E, Pedrazzoli P, Montagna D. In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status. J Immunother 2018;41:190-200. [PMID: 29293164 DOI: 10.1097/CJI.0000000000000205] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
130 Teufel A, Marquardt JU, Galle PR. Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/β-catenin. J Hepatol 2013;58:622-4. [PMID: 23063568 DOI: 10.1016/j.jhep.2012.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
131 Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer 2012;11:85-7. [PMID: 22169039 DOI: 10.1016/j.clcc.2011.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Proc Natl Acad Sci U S A 2019;116:22122-31. [PMID: 31611389 DOI: 10.1073/pnas.1908353116] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
133 Bodelón G, Montes-García V, Fernández-López C, Pastoriza-Santos I, Pérez-Juste J, Liz-Marzán LM. Au@pNIPAM SERRS Tags for Multiplex Immunophenotyping Cellular Receptors and Imaging Tumor Cells. Small 2015;11:4149-57. [PMID: 25939486 DOI: 10.1002/smll.201500269] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
134 Melton SD, Genta RM, Souza RF. Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol. 2010;7:620-628. [PMID: 20924366 DOI: 10.1038/nrgastro.2010.153] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
135 Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Mugnoz FG, Cantore M, Ricci S, Catalano V, Mambrini A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol 2015; 7(6): 47-54 [PMID: 26090075 DOI: 10.4251/wjgo.v7.i6.47] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
136 Wong YK, Tsang HF, Xue VW, Chan CM, Au TC, Cho WC, Chan LW, Wong SC. Applications of digital PCR in precision medicine. Expert Review of Precision Medicine and Drug Development 2017;2:177-86. [DOI: 10.1080/23808993.2017.1347482] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
137 Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 2016;7:11363. [PMID: 27193833 DOI: 10.1038/ncomms11363] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
138 Nussinov R, Muratcioglu S, Tsai C, Jang H, Gursoy A, Keskin O. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? Expert Opinion on Therapeutic Targets 2016;20:831-42. [DOI: 10.1517/14728222.2016.1135131] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
139 Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 2012;17:346-58. [PMID: 22334453 DOI: 10.1634/theoncologist.2011-0311] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
140 Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, Sakai Y, Inoue M. In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PLoS One 2017;12:e0174151. [PMID: 28301591 DOI: 10.1371/journal.pone.0174151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
141 Shanmugam V, Ramanathan RK, Lavender NA, Sinari S, Chadha M, Liang WS, Kurdoglu A, Izatt T, Christoforides A, Benson H, Phillips L, Baker A, Murray C, Hostetter G, Von Hoff DD, Craig DW, Carpten JD. Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. BMC Med Genomics 2014;7:36. [PMID: 24943349 DOI: 10.1186/1755-8794-7-36] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
142 Zou Z, Qi P, Qing Z, Zheng J, Yang S, Chen W, Yang R. Technologies for analysis of circulating tumour DNA: Progress and promise. TrAC Trends in Analytical Chemistry 2017;97:36-49. [DOI: 10.1016/j.trac.2017.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
143 Zuo Q, Shi M, Chen J, Liao W. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. Biomedicine & Pharmacotherapy 2011;65:168-74. [DOI: 10.1016/j.biopha.2011.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
144 Matallanas D, Romano D, Al-Mulla F, O’Neill E, Al-Ali W, Crespo P, Doyle B, Nixon C, Sansom O, Drosten M. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell. 2011;44:893-906. [PMID: 22195963 DOI: 10.1016/j.molcel.2011.10.016] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 10.1] [Reference Citation Analysis]
145 Wiesweg M, Ting S, Reis H, Worm K, Kasper S, Tewes M, Welt A, Richly H, Meiler J, Bauer S, Hense J, Gauler TC, Köhler J, Eberhardt WE, Darwiche K, Freitag L, Stamatis G, Breitenbücher F, Wohlschlaeger J, Theegarten D, Derks C, Cortes-incio D, Linden G, Skottky S, Lütkes P, Dechêne A, Paul A, Markus P, Schmid KW, Schuler M. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. European Journal of Cancer 2013;49:3076-82. [DOI: 10.1016/j.ejca.2013.06.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
146 Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 2011;30:561-574. [PMID: 20956938 DOI: 10.1038/onc.2010.430] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 7.6] [Reference Citation Analysis]
147 Wang D, Xia D, Dubois RN. The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers (Basel) 2011;3:3894-908. [PMID: 24213116 DOI: 10.3390/cancers3043894] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
148 Chang CC, Lin CC, Wang CH, Huang CC, Ke TW, Wei PL, Yeh KT, Hsu KC, Hsu NY, Cheng YW. miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation. Oncol Lett 2018;15:8107-17. [PMID: 29731918 DOI: 10.3892/ol.2018.8295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
149 Biswal BN, Das SN, Das BK, Rath R. Alteration of cellular metabolism in cancer cells and its therapeutic prospects. J Oral Maxillofac Pathol 2017;21:244-51. [PMID: 28932034 DOI: 10.4103/jomfp.JOMFP_60_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Murugan AK, Munirajan AK, Tsuchida N. Genetic deregulation of the PIK3CA oncogene in oral cancer. Cancer Lett. 2013;338:193-203. [PMID: 23597702 DOI: 10.1016/j.canlet.2013.04.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
151 Bruera G, Cannita K, Di Giacomo D, Lamy A, Frébourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Med 2013;11:59. [PMID: 23497191 DOI: 10.1186/1741-7015-11-59] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
152 Gerbig S, Golf O, Balog J, Denes J, Baranyai Z, Zarand A, Raso E, Timar J, Takats Z. Analysis of colorectal adenocarcinoma tissue by desorption electrospray ionization mass spectrometric imaging. Anal Bioanal Chem 2012;403:2315-25. [PMID: 22447214 DOI: 10.1007/s00216-012-5841-x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
153 López F, García Inclán C, Pérez-Escuredo J, Alvarez Marcos C, Scola B, Suárez C, Llorente JL, Hermsen MA. KRAS and BRAF mutations in sinonasal cancer. Oral Oncol 2012;48:692-7. [PMID: 22459936 DOI: 10.1016/j.oraloncology.2012.02.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
154 Hu J, Yan WY, Xie L, Cheng L, Yang M, Li L, Shi J, Liu BR, Qian XP. Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. Medicine (Baltimore) 2016;95:e5649. [PMID: 27977612 DOI: 10.1097/MD.0000000000005649] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
155 Shen W, Deng H, Ren Y, Gao Z. An electronic sensor array for label-free detection of single-nucleotide polymorphisms. Biosensors and Bioelectronics 2013;43:165-72. [DOI: 10.1016/j.bios.2012.12.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
156 Steinbach C, Steinbrücker C, Pollok S, Walther K, Clement JH, Chen Y, Petersen I, Cialla-May D, Weber K, Popp J. KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology. Analyst 2015;140:2747-54. [PMID: 25706807 DOI: 10.1039/c4an02086c] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
157 Aran V. K-RAS4A: Lead or Supporting Role in Cancer Biology? Front Mol Biosci 2021;8:729830. [PMID: 34604308 DOI: 10.3389/fmolb.2021.729830] [Reference Citation Analysis]
158 Wilson PM, Lenz H. Integrating Biomarkers Into Clinical Decision Making for Colorectal Cancer. Clinical Colorectal Cancer 2010;9:S16-27. [DOI: 10.3816/ccc.2010.s.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
159 Simpson PT, Vargas A, Al-ejeh F, Khanna KK, Chenevix-trench G, Lakhani SR. Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. Human Pathology 2011;42:153-65. [DOI: 10.1016/j.humpath.2010.07.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
160 You XH, Jiang YH, Fang Z, Sun F, Li Y, Wang W, Xia ZJ, Wang XZ, Ying HQ. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open. 2020;4:e000605. [PMID: 32132090 DOI: 10.1136/esmoopen-2019-000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
161 Ottaiano A, Scala S, Santorsola M, Trotta AM, D'Alterio C, Portella L, Clemente O, Nappi A, Zanaletti N, De Stefano A, Avallone A, Granata V, Notariello C, Luce A, Lombardi A, Picone C, Petrillo A, Perri F, Tatangelo F, Di Mauro A, Albino V, Izzo F, Rega D, Pace U, Di Marzo M, Chiodini P, De Feo G, Del Prete P, Botti G, Delrio P, Caraglia M, Nasti G. Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Ther Adv Med Oncol 2021;13:1758835921989223. [PMID: 33854566 DOI: 10.1177/1758835921989223] [Reference Citation Analysis]
162 Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L. BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent. Sci Signal 2015;8:ra38. [PMID: 25900832 DOI: 10.1126/scisignal.2005886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
163 Buisine M, Cattan S, Wacrenier A, Leclerc J, Lejeune S. Identification of a Patient With Atypical MUTYH -Associated Polyposis Through Detection of the KRAS c.34G>T Mutation in Liver Metastasis. JCO 2013;31:e125-7. [DOI: 10.1200/jco.2012.44.7391] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
164 Ottaiano A, Normanno N, Facchini S, Cassata A, Nappi A, Romano C, Silvestro L, De Stefano A, Rachiglio AM, Roma C, Maiello MR, Scala S, Delrio P, Tatangelo F, Di Mauro A, Botti G, Avallone A, Nasti G. Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Cancers (Basel) 2020;12:E1919. [PMID: 32708575 DOI: 10.3390/cancers12071919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
165 Karagkounis G, Kalady MF. Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information? Clin Colon Rectal Surg 2017;30:415-22. [PMID: 29184477 DOI: 10.1055/s-0037-1606373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Hodoglugil U, Carrillo MW, Hebert JM, Karachaliou N, Rosell RC, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Pharmacogenet Genomics 2013;23:636-42. [PMID: 23962910 DOI: 10.1097/FPC.0b013e3283655091] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
167 Li W, Zhi W, Zou S, Qiu T, Ling Y, Shan L, Shi S, Ying J. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS One 2015;10:e0128202. [PMID: 26042813 DOI: 10.1371/journal.pone.0128202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
168 Raisch J, Côté-Biron A, Rivard N. A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers. Cancers (Basel) 2019;11:E1162. [PMID: 31412666 DOI: 10.3390/cancers11081162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
169 Yuan Y, Weidhaas JB. Functional microRNA binding site variants. Mol Oncol. 2019;13:4-8. [PMID: 30536617 DOI: 10.1002/1878-0261.12421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
170 Hsu JY, Chang JY, Chang KY, Chang WC, Chen BK. Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamous cell carcinoma metastasis via up-regulation of fibronectin. FASEB J 2017;31:4265-76. [PMID: 28596235 DOI: 10.1096/fj.201700156R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
171 He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med 2011;17:244-51. [PMID: 21388883 DOI: 10.1016/j.molmed.2011.01.007] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
172 Tsuchida N, Murugan AK, Grieco M. Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget 2016;7:46717-33. [PMID: 27102293 DOI: 10.18632/oncotarget.8773] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
173 Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open 2016;1:e000088. [PMID: 27843640 DOI: 10.1136/esmoopen-2016-000088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
174 Friedrich T, Richter B, Gaiser T, Weiss C, Janssen KP, Einwächter H, Schmid RM, Ebert MP, Burgermeister E. Deficiency of caveolin-1 in Apc(min/+) mice promotes colorectal tumorigenesis. Carcinogenesis 2013;34:2109-18. [PMID: 23640045 DOI: 10.1093/carcin/bgt142] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
175 Wang YL, Yuan Y, Luo XX, Hu GY, Gong P. Genetic Variants in EGFR/PLCE1 Pathway Are Associated with Prognosis of Esophageal Squamous Cell Carcinoma after Radical Resection. Curr Med Sci 2019;39:385-90. [PMID: 31209807 DOI: 10.1007/s11596-019-2047-x] [Reference Citation Analysis]
176 McFall T, Stites EC. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Rep 2021;37:110096. [PMID: 34910921 DOI: 10.1016/j.celrep.2021.110096] [Reference Citation Analysis]
177 Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn. 2010;12:780-786. [PMID: 20864634 DOI: 10.2353/jmoldx.2010.100016] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
178 Wainberg ZA, Drakaki A. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. Expert Opinion on Biological Therapy 2015;15:1205-20. [DOI: 10.1517/14712598.2015.1050375] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
179 Hara Y, Minami Y, Yoshimoto S, Hayashi N, Yamasaki A, Ueda S, Masuko K, Masuko T. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells. Cancer Med 2020;9:302-12. [PMID: 31709772 DOI: 10.1002/cam4.2689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
180 Eifert C, Pantazi A, Sun R, Xu J, Cingolani P, Heyer J, Russell M, Lvova M, Ring J, Tse JY, Lyle S, Protopopov A. Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Per Med 2017;14:309-25. [PMID: 28890729 DOI: 10.2217/pme-2017-0011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
181 Nagaraju GP, Alese OB, Landry J, Diaz R, El-Rayes BF. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. Oncotarget 2014;5:9980-91. [PMID: 25296971 DOI: 10.18632/oncotarget.2484] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
182 Erazo-Oliveras A, Fuentes NR, Wright RC, Chapkin RS. Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents. Cancer Metastasis Rev 2018;37:519-44. [PMID: 29860560 DOI: 10.1007/s10555-018-9733-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
183 Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J 2012;12:277-86. [PMID: 22760589 DOI: 10.1038/tpj.2012.28] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
184 Wang Z, Zhang C, Wang Z, Meng X, Liu X, Han B, Duan C, Cai J, Hao Z, Chen M, Jiang T, Li Y, Jiang C, Wang H. MiR-134, epigenetically silenced in gliomas, could mitigate the malignant phenotype by targeting KRAS. Carcinogenesis 2018;39:389-96. [DOI: 10.1093/carcin/bgy022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
185 Ottaiano A, Petito A, Santorsola M, Gigantino V, Capuozzo M, Fontanella D, Di Franco R, Borzillo V, Buonopane S, Ravo V, Scipilliti E, Totaro G, Serra M, Ametrano G, Penta R, Tatangelo F, Scognamiglio G, Di Mauro A, Di Bonito M, Napolitano M, Scala S, Rea G, Santagata S, Lombardi A, Grimaldi A, Caputo C, Crispo A, Celentano E, De Feo G, Circelli L, Savarese G, Ruggiero R, Perri F, Granata V, Botti G, Caraglia M, Nasti G, Muto P. Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. Cancers (Basel) 2021;13:4236. [PMID: 34439390 DOI: 10.3390/cancers13164236] [Reference Citation Analysis]
186 Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, La Porta ML, Iannaccone A, Micheli F, Santangelo M, Bergantino F, Costantini S, De Luca A. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem 2013;114:514-24. [PMID: 22991232 DOI: 10.1002/jcb.24401] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
187 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
188 Bonzheim I, Fend F. [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology]. Pathologe 2014;35:93-105. [PMID: 24496994 DOI: 10.1007/s00292-013-1798-6] [Reference Citation Analysis]
189 Rachiglio AM, Esposito Abate R, Sacco A, Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco G, Romano C, Nappi A, Iaffaioli RV, Tatangelo F, Botti G, Ciardiello F, Maiello MR, De Luca A, Normanno N. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget 2016;7:66595-605. [PMID: 27448974 DOI: 10.18632/oncotarget.10704] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 14.0] [Reference Citation Analysis]
190 Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699-731. [PMID: 20584808 DOI: 10.1634/theoncologist.2010-0025] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
191 Kim DD, Eng C. The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opin Investig Drugs 2012;21:1775-88. [PMID: 22978346 DOI: 10.1517/13543784.2012.721353] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
192 Orentas RJ, Lee DW, Mackall C. Immunotherapy targets in pediatric cancer. Front Oncol 2012;2:3. [PMID: 22645714 DOI: 10.3389/fonc.2012.00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
193 You KS, Yi YW, Cho J, Park JS, Seong YS. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:589. [PMID: 34207383 DOI: 10.3390/ph14060589] [Reference Citation Analysis]
194 Ma T, Liu H, Sun X, Gao L, Shi J, Zhao H, Jia B, Wang F, Liu Z. Serial in Vivo Imaging Using a Fluorescence Probe Allows Identification of Tumor Early Response to Cetuximab Immunotherapy. Mol Pharmaceutics 2015;12:10-7. [DOI: 10.1021/mp5002944] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
195 Pecci F, Cantini L, Bittoni A, Lenci E, Lupi A, Crocetti S, Giglio E, Giampieri R, Berardi R. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. Curr Treat Options Oncol 2021;22:69. [PMID: 34110510 DOI: 10.1007/s11864-021-00870-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Santhosh S, Kumar P, Ramprasad V, Chaudhuri A. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. Future Oncology 2015;11:279-93. [DOI: 10.2217/fon.14.198] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
197 Pacini L, Bastianelli D, Ponti D, Rosa P, Petrozza V, Giannini G, Ragona G, Calogero A. Direct correlation between double K-RAS mutation and mucinous carcinoma. A case report. Appl Immunohistochem Mol Morphol 2015;23:e4-7. [PMID: 25675084 DOI: 10.1097/PAI.0000000000000176] [Reference Citation Analysis]
198 Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357:582-590. [PMID: 25497009 DOI: 10.1016/j.canlet.2014.12.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
199 Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 2012;118:5550-9. [PMID: 22569880 DOI: 10.1002/cncr.27596] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
200 García-Alfonso P, Grande E, Polo E, Afonso R, Reina JJ, Jorge M, Campos JM, Martínez V, Angeles C, Montagut C. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis 2014;17:805-21. [PMID: 24793846 DOI: 10.1007/s10456-014-9433-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
201 Lin C, Lin J, Lin T, Chen W, Yang S, Wang H, Lan Y, Jiang J, Yang M, Chang S. The prognostic role of microsatellite instability, codon-specific KRAS , and BRAF mutations in colon cancer: Prognostic Factors in Colon Cancer. J Surg Oncol 2014;110:451-7. [DOI: 10.1002/jso.23675] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
202 Claes B, Buysschaert I, Lambrechts D. Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. Heredity 2010;105:152-60. [DOI: 10.1038/hdy.2010.42] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
203 Ohishi T, Kato Y, Kaneko MK, Ohba SI, Inoue H, Harakawa A, Kawada M. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation. Int J Mol Sci 2020;21:E6037. [PMID: 32839411 DOI: 10.3390/ijms21176037] [Reference Citation Analysis]
204 Bell DW. Our changing view of the genomic landscape of cancer. J Pathol 2010;220:231-43. [PMID: 19918804 DOI: 10.1002/path.2645] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
205 Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1-10. [PMID: 29564165 DOI: 10.21037/jgo.2017.10.14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
206 Chen J, Huang XF, Katsifis A. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem. 2010;111:1082-1086. [PMID: 21053280 DOI: 10.1002/jcb.22905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
207 Desir S, Wong P, Turbyville T, Chen, Shetty M, Clark C, Zhai E, Romin Y, Manova-Todorova K, Starr TK, Nissley DV, Steer CJ, Subramanian S, Lou E. Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells. Cancers (Basel) 2019;11:E892. [PMID: 31247990 DOI: 10.3390/cancers11070892] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
208 Yoshino T, Muro K, Yamaguchi K, Nishina T, Denda T, Kudo T, Okamoto W, Taniguchi H, Akagi K, Kajiwara T, Hironaka S, Satoh T. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. EBioMedicine 2015;2:317-23. [PMID: 26137573 DOI: 10.1016/j.ebiom.2015.02.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
209 Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, Van Cutsem E. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 2011;6:133-45. [PMID: 21630045 DOI: 10.1007/s11523-011-0181-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
210 Masi G, Fornaro L, Caparello C, Falcone A. Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. Future Oncology 2011;7:1299-323. [DOI: 10.2217/fon.11.108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
211 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
212 Geng R, Tan X, Wu J, Pan Z, Yi M, Shi W, Liu R, Yao C, Wang G, Lin J, Qiu L, Huang W, Chen S. RNF183 promotes proliferation and metastasis of colorectal cancer cells via activation of NF-κB-IL-8 axis. Cell Death Dis 2017;8:e2994. [PMID: 28796265 DOI: 10.1038/cddis.2017.400] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
213 Yang WJ, Shen XJ, Ma XX, Tan ZG, Song Y, Guo YT, Yuan M. Correlation of human epidermal growth factor receptor protein expression and colorectal cancer. World J Gastroenterol 2015; 21(28): 8687-8696 [PMID: 26229411 DOI: 10.3748/wjg.v21.i28.8687] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
214 Vakil L, Najafipour R, Rakhshani N, Zamani F, Morakabati A, Javadi A. Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer. Tumour Biol 2016;37:8841-8. [PMID: 26749281 DOI: 10.1007/s13277-015-4723-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
215 Welt A, Tewes M, Aktas B, O Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S. Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. Breast Cancer Res Treat 2013;142:81-8. [PMID: 24122392 DOI: 10.1007/s10549-013-2718-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
216 Fornaro L, Masi G, Loupakis F, Vasile E, Falcone A. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin Pharmacother. 2010;11:63-77. [PMID: 20001430 DOI: 10.1517/14656560903427997] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
217 Normanno N, Tejpar S, Ciardiello F. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2010;102:573; author reply 573-5. [PMID: 20305131 DOI: 10.1093/jnci/djq064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
218 Liu J, Hu J, Cheng L, Ren W, Yang M, Liu B, Xie L, Qian X. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. Onco Targets Ther 2016;9:557-65. [PMID: 26869800 DOI: 10.2147/OTT.S86966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
219 Patil N, Abba M, Allgayer H. Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics 2012;6:221-31. [PMID: 22904614 DOI: 10.2147/BTT.S24217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
220 Wu L, Garrido-Maestu A, Guerreiro JRL, Carvalho S, Abalde-Cela S, Prado M, Diéguez L. Amplification-free SERS analysis of DNA mutation in cancer cells with single-base sensitivity. Nanoscale 2019;11:7781-9. [PMID: 30951061 DOI: 10.1039/c9nr00501c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
221 Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Exploration of Targeted Anti-tumor Therapy 2020;1:53-70. [DOI: 10.37349/etat.2020.00004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, Nappi O, Iaffaioli V, Botti G, Normanno N. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 2010;11:1169-79. [DOI: 10.2217/pgs.10.86] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
223 Wang X, Luo X, Tian Y, Wu T, Weng J, Li Z, Ye F, Huang X. Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer. ACS Chem Biol 2021;16:724-30. [PMID: 33829754 DOI: 10.1021/acschembio.1c00022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, Faria P, Pereira E, Skalova A, Bilous M, Balleine RL, Do H, Dobrovic A, Fox S, Franco M, Reynolds B, Khanna KK, Cummings M, Chenevix-Trench G, Lakhani SR. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 2010;12:R46. [PMID: 20604919 DOI: 10.1186/bcr2603] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 7.2] [Reference Citation Analysis]
225 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. Int J Oncol 2014;44:1820-30. [PMID: 24715238 DOI: 10.3892/ijo.2014.2369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
226 Atsumi J, Hanami T, Enokida Y, Ogawa H, Delobel D, Mitani Y, Kimura Y, Soma T, Tagami M, Takase Y, Ichihara T, Takeyoshi I, Usui K, Hayashizaki Y, Shimizu K. Eprobe-mediated screening system for somatic mutations in the KRAS locus. Oncol Rep 2015;33:2719-27. [PMID: 25823645 DOI: 10.3892/or.2015.3883] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
227 Schneider MA, Eden J, Pache B, Laminger F, Lopez-Lopez V, Steffen T, Hübner M, Kober F, Roka S, Campos PC, Roth L, Gupta A, Siebenhüner A, Kepenekian V, Passot G, Gertsch P, Glehen O, Lehmann K. Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin. Ann Surg 2018;268:845-53. [PMID: 30303876 DOI: 10.1097/SLA.0000000000002899] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 12.7] [Reference Citation Analysis]
228 Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: the past 20 years. Oral Oncol. 2012;48:383-392. [PMID: 22240207 DOI: 10.1016/j.oraloncology.2011.12.006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
229 Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122:2698-2707. [PMID: 27244540 DOI: 10.1002/cncr.30085] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
230 Trung NT, Hoan NX, Trung PQ, Binh MT, Van Tong H, Toan NL, Bang MH, Song LH. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma. Sci Rep 2020;10:8181. [PMID: 32424223 DOI: 10.1038/s41598-020-65213-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
231 Marbaniang C, Kma L. Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells. Asian Pac J Cancer Prev 2018;19:2377-90. [PMID: 30255690 DOI: 10.22034/APJCP.2018.19.9.2377] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
232 Coutinho AK, Prolla G, Weschenfelder R. BRAF, KRAS, and Phosphatidylinositol 3-Kinase in the Management of Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2013;9:57-67. [DOI: 10.1007/s11888-012-0152-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Zhang J, Jiang X, Yin J, Dou S, Xie X, Liu T, Wang Y, Wang S, Zhou X, Zhang D, Jiang H. RNF141 interacts with KRAS to promote colorectal cancer progression. Oncogene 2021. [PMID: 34345014 DOI: 10.1038/s41388-021-01877-4] [Reference Citation Analysis]
234 Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One 2011;6:e29146. [PMID: 22216189 DOI: 10.1371/journal.pone.0029146] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
235 Xing J, Myers RE, He X, Qu F, Zhou F, Ma X, Hyslop T, Bao G, Wan S, Yang H, Chen Z. GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. Eur J Cancer 2011;47:1699-707. [PMID: 21402474 DOI: 10.1016/j.ejca.2011.02.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
236 Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014;106:dju215. [PMID: 25099740 DOI: 10.1093/jnci/dju215] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 8.0] [Reference Citation Analysis]
237 de Souza JE, Fonseca AF, Valieris R, Carraro DM, Wang JY, Kolodner RD, de Souza SJ. S-score: a scoring system for the identification and prioritization of predicted cancer genes. PLoS One 2014;9:e94147. [PMID: 24710071 DOI: 10.1371/journal.pone.0094147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
238 McGregor M, Price TJ. Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncol 2018;14:2437-59. [PMID: 29737864 DOI: 10.2217/fon-2017-0711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
239 Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T. Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. Oncotarget 2017;8:82773-83. [PMID: 29137301 DOI: 10.18632/oncotarget.19797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
240 Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S. A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. Clin Colorectal Cancer 2015;14:154-61. [PMID: 25861837 DOI: 10.1016/j.clcc.2015.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
241 Liu Y, Meucci S, Sheng L, Keilholz U. Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. Oncotarget 2017;8:77928-41. [PMID: 29100436 DOI: 10.18632/oncotarget.18272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
242 Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer 2014;134:596-605. [PMID: 23873170 DOI: 10.1002/ijc.28390] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
243 De Vriendt V, De Roock W, Di Narzo AF, Tian S, Biesmans B, Jacobs B, Budinska E, Sagaert X, Rossi S, D’ario G, Delorenzi M, Simon I, Vecchione L, Tejpar S. DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers 2013;18:516-24. [DOI: 10.3109/1354750x.2013.819038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
244 Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, Carnie A, Tarasova N, Mkrtichyan M, Berzofsky JA, Whiteside TL, Khleif SN. Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunol Res 2016;4:354-65. [PMID: 26880715 DOI: 10.1158/2326-6066.CIR-15-0241] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
245 Schokoroy S, Juster D, Kloog Y, Pinkas-Kramarski R. Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death. PLoS One 2013;8:e75269. [PMID: 24086490 DOI: 10.1371/journal.pone.0075269] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
246 Bando I, Cillero L, Sanz-Ortega J, Llovet P, Pescador P, Ferrer M, de la Hoya M, Sastre J, García ED, Caldés T. Study of KRAS new predictive marker in a clinical laboratory. Clin Transl Oncol 2012;14:937-42. [PMID: 22865324 DOI: 10.1007/s12094-012-0886-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
247 Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol. 2013;139:201-209. [PMID: 23015072 DOI: 10.1007/s00432-012-1319-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
248 Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol 2014;11:446-59. [DOI: 10.1038/nrclinonc.2014.90] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
249 Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26:1710-1714. [PMID: 25851630 DOI: 10.1093/annonc/mdv176] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 12.9] [Reference Citation Analysis]
250 Buzdin A, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E, Sekacheva M, Kim E, Gaifullin N, Giese A, Seryakov A, Rumiantsev P, Moshkovskii S, Moiseev A. RNA sequencing for research and diagnostics in clinical oncology. Semin Cancer Biol 2020;60:311-23. [PMID: 31412295 DOI: 10.1016/j.semcancer.2019.07.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
251 Kim Y, Kim J, Lee HD, Jeong J, Lee W, Lee KA. Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. PLoS One. 2013;8:e79014. [PMID: 24205362 DOI: 10.1371/journal.pone.0079014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
252 Kim Y, Dillon PM, Park T, Lee JK. CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget 2018;9:1091-106. [PMID: 29416679 DOI: 10.18632/oncotarget.23124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
253 Chakrabarti M, Jang H, Nussinov R. Comparison of the Conformations of KRAS Isoforms, K-Ras4A and K-Ras4B, Points to Similarities and Significant Differences. J Phys Chem B 2016;120:667-79. [PMID: 26761128 DOI: 10.1021/acs.jpcb.5b11110] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
254 Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F. Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer 2011;71:283-90. [PMID: 20619923 DOI: 10.1016/j.lungcan.2010.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
255 Zhang M, Zhao S, Tan C, Gu Y, He X, Du X, Li D, Wei P. RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA. J Exp Clin Cancer Res 2021;40:200. [PMID: 34154626 DOI: 10.1186/s13046-021-01994-8] [Reference Citation Analysis]
256 Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken JH, Dequeker EM. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. J Mol Diagn 2014;16:371-7. [PMID: 24631467 DOI: 10.1016/j.jmoldx.2014.01.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
257 Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Med 2012;10:135. [PMID: 23136868 DOI: 10.1186/1741-7015-10-135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
258 Gauthier M, Laroye C, Bensoussan D, Boura C, Decot V. Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells. Crit Rev Oncol Hematol 2021;160:103261. [PMID: 33607229 DOI: 10.1016/j.critrevonc.2021.103261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
259 Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:154702. [PMID: 25295247 DOI: 10.1155/2014/154702] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
260 Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer. 2010;46:1703-1711. [PMID: 20399639 DOI: 10.1016/j.ejca.2010.03.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
261 Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. JCI Insight 2019;5:127552. [PMID: 31237864 DOI: 10.1172/jci.insight.127552] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
262 Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR, Cook SJ. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013;32:3059-70. [PMID: 22869148 DOI: 10.1038/onc.2012.319] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 8.7] [Reference Citation Analysis]
263 Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol 2011;2011:285840. [PMID: 22312501 DOI: 10.1155/2011/285840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
264 Huang EH, Johnson LA, Eaton K, Hynes MJ, Carpentino JE, Higgins PD. Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice. Dig Dis Sci. 2010;55:3086-3094. [PMID: 20186482 DOI: 10.1007/s10620-010-1157-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
265 Barbon C, Margonis GA, Andreatos N, Rezaee N, Sasaki K, Buettner S, Damaskos C, Pawlik TM, He J, Wolfgang CL, Weiss MJ. Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing? J Gastrointest Surg 2018;22:1286-96. [DOI: 10.1007/s11605-018-3766-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
266 Kim JY, Park SG, Kim KS, Choi YH, Kim NK. The Krüppel-like factor (KLF5) as a predictive biomarker in preoperative chemoradiation therapy for rectal cancer. Ann Surg Treat Res 2019;97:83-92. [PMID: 31388510 DOI: 10.4174/astr.2019.97.2.83] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
267 Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res 2019;25:6899-908. [PMID: 31263029 DOI: 10.1158/1078-0432.CCR-19-0823] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 8.7] [Reference Citation Analysis]
268 Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel) 2021;13:4803. [PMID: 34638288 DOI: 10.3390/cancers13194803] [Reference Citation Analysis]
269 Cazzanelli G, Pereira F, Alves S, Francisco R, Azevedo L, Dias Carvalho P, Almeida A, Côrte-Real M, Oliveira MJ, Lucas C, Sousa MJ, Preto A. The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells 2018;7:E14. [PMID: 29463063 DOI: 10.3390/cells7020014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
270 Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz H, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll H, Sobrero A, Tabernero J. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Annals of Oncology 2010;21:vi1-vi10. [DOI: 10.1093/annonc/mdq273] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
271 Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11:777-792. [PMID: 21293176 DOI: 10.4161/cbt.11.9.15050] [Cited by in Crossref: 148] [Cited by in F6Publishing: 133] [Article Influence: 13.5] [Reference Citation Analysis]
272 Chen F, Alphonse MP, Liu Y, Liu Q. Targeting Mutant KRAS for Anticancer Therapy. CTMC 2019;19:2098-113. [DOI: 10.2174/1568026619666190902151307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, Garcia-Aguilar J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol 2013;20:2166-71. [PMID: 23456389 DOI: 10.1245/s10434-013-2910-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
274 Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219 [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
275 Tahir R, Renuse S, Udainiya S, Madugundu AK, Cutler JA, Nirujogi RS, Na CH, Xu Y, Wu X, Pandey A. Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles. J Proteome Res 2021;20:670-83. [PMID: 32986951 DOI: 10.1021/acs.jproteome.0c00587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
276 Martinelli E, Morgillo F, Troiani T, Ciardiello F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat Rev. 2017;53:61-69. [PMID: 28073102 DOI: 10.1016/j.ctrv.2016.12.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 9.2] [Reference Citation Analysis]
277 Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer. 2010;10:302. [PMID: 20565817 DOI: 10.1186/1471-2407-10-302] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
278 Bruin SC, He Y, Mikolajewska-Hanclich I, Liefers GJ, Klijn C, Vincent A, Verwaal VJ, de Groot KA, Morreau H, van Velthuysen ML, Tollenaar RA, van 't Veer LJ. Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer 2011;105:281-7. [PMID: 21673680 DOI: 10.1038/bjc.2011.184] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
279 Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012;148:639-50. [PMID: 22341439 DOI: 10.1016/j.cell.2011.12.033] [Cited by in Crossref: 204] [Cited by in F6Publishing: 195] [Article Influence: 20.4] [Reference Citation Analysis]
280 Cushman SM, Jiang C, Hatch AJ, Shterev I, Sibley AB, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 2015;21:1078-86. [PMID: 25520391 DOI: 10.1158/1078-0432.CCR-14-2313] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]